ROLE OF THE UBIQUITIN-PROTEASOME PROTEIN DEGRADATION PATHWAY IN CARCINOGENESIS, TUMOR PROGRESSION AND SUSCEPTIBILITY TO TUMOR TREATMENT

The review summarizes data on involvement of the proteasomes and other enzymes performing the ubiquitin-mediated proteolysis in carcinogenesis, tumor biology and mechanisms of action of antitumor drugs. Increased or decreased susceptibility of oncoproteins and tumor suppressors can give rise to tumorigenesis. Proteasome composition and proteasome activity is altered in neoplastic cells. Novel antitumor drugs can be developed from the proteasome inhibitors.